ChemicalBook > Product Catalog >API >Antineoplastic agents >Antibiotics anticancer drugs >Adriamycin

Adriamycin

Adriamycin Structure
CAS No.
23214-92-8
Chemical Name:
Adriamycin
Synonyms
DOXORUBICIN;Doxil;Rubex;Adriamycin PFS;HydroxydaunoMycin;Doxorubicin hydrohloride;10-((3-amino-2,3,6-trideoxy-alpha-l-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;(1s,3s)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside;(8S-cis)-10-(3-Amino-2,3,6-Trideoxy-alpha-L-Lyxo-Hexopyranosyl)Oxy-7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-5,12-Naphthacenedione;(8S)-10-((4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
CBNumber:
CB1170865
Molecular Formula:
C27H29NO11
Molecular Weight:
543.53
MOL File:
23214-92-8.mol
Modify Date:
2024/8/21 22:41:43

Adriamycin Properties

Melting point 205°C
Boiling point 617.77°C (rough estimate)
Density 1.3783 (rough estimate)
refractive index 1.6400 (estimate)
storage temp. Keep in dark place,Sealed in dry,2-8°C
solubility ≥27.2 mg/mL in DMSO; insoluble in EtOH; ≥24.8 mg/mL in H2O with ultrasonic
form solid
pka pKa 8.2 (Uncertain)
Water Solubility Soluble
CAS DataBase Reference 23214-92-8
IARC 2A (Vol. 10, Sup 7) 1987
EPA Substance Registry System Doxorubicin (23214-92-8)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07,GHS08
Signal word  Danger
Hazard statements  H302-H315-H319-H335-H350-H362
Precautionary statements  P260-P263-P280
HS Code  2941900000
Toxicity An anthracycline cytotoxic antineoplastic that is produced by Streptomyces peucetius. The LD50 in mice is 9.4 mg/kg, i.v. It is a carcinogen that inhibits DNA and RNA synthesis by intercalating in double-stranded DNA with the amino sugar in the minor groove and the 90-OH group of the anthracycline ring hydrogen-bonded to the adjacent guanine. It also alters membrane fluidity and ion transport, and generates free radicals through a cytochrome P450-mediated reductive process. In humans, it causes alopecia, stomatitis, nausea, vomiting, diarrhea, cardiotoxicity (manifested by tachycardia), and potentially fatal congestive heart failure.

Adriamycin Chemical Properties,Uses,Production

Chemical Properties

Adriamycin is an orange to red cake-like or needle-like crystalline solid.

Uses

Doxorubicin (adriamycin) is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumour agent for the treatment of a wide range of cancers. Doxorubicin also exhibits anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.

Indications

Doxorubicin binds tightly to DNA by its ability to intercalate between base pairs and therefore is preferentially concentrated in nuclear structures. Intercalation results in steric hindrance, hence production of single-strand breaks in DNA and inhibition of DNA synthesis and DNA-dependent RNA synthesis. The enzyme topoisomerase II is thought to be involved in the generation of DNA strand breaks by the anthracyclines. Cells in S-phase are most sensitive to doxorubicin, although cytotoxicity also occurs in other phases of the cell cycle.

Mechanism of action

Doxorubicin is not absorbed orally, and because of its ability to cause tissue necrosis must not be injected intramuscularly or subcutaneously. Distribution studies indicate rapid uptake in all tissues except the CNS. Extensive tissue binding, primarily intranuclear, accounts for the prolonged elimination half-life.The drug is extensively metabolized in the liver to hydroxylated and conjugated metabolites and to aglycones that are primarily excreted in the bile.

Clinical Use

Doxorubicin is one of the most effective agents used in the treatment of carcinomas of the breast, ovary, endometrium, bladder, and thyroid and in oat cell cancer of the lung. It is included in several combination regimens for diffuse lymphomas and Hodgkin’s disease. Doxorubicin can be used as an alternative to daunorubicin in acute leukemias and is useful in Ewing’s sarcoma, osteogenic sarcoma, soft-tissue sarcomas, and neuroblastoma. Some activity has been reported in non–oat cell lung cancer, multiple myeloma, and adenocarcinomas of the stomach, prostate, and testis.

Side effects

The most important toxicities caused by doxorubicin involve the heart and bone marrow.Acutely, doxorubicin may cause transient cardiac arrhythmias and depression of myocardial function. Doxorubicin may cause radiation recall reactions, with flare-ups of dermatitis, stomatitis, or esophagitis that had been produced previously by radiation therapy. Less severe toxicities include phlebitis and sclerosis of veins used for injection, hyperpigmentation of nail beds and skin creases, and conjunctivitis. Because of its intense red color, doxorubicin will impart a reddish color to the urine for 1 or 2 days after administration.

Safety Profile

Confirmed carcinogen with experimental carcinogenic, neoplastigenic, and tumorigenic data. Poison by intraperitoneal, subcutaneous, parenteral, and intravenous routes. Human systemic effects by intravenous route: cardiac myopathy including infarction, nausea or vomiting, and effects on the hair. An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of NO, and HCl

Potential Exposure

An antibiotic product from streptomyces, used as anticancer drug

Carcinogenicity

Adriamycin is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.

Shipping

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required.

Incompatibilities

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides

Waste Disposal

It is inappropriate and possibly dangerous to the environment to dispose of expired or waste pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Adriamycin Preparation Products And Raw materials

Global( 259)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
AVD pharmaceuticals Pvt Ltd +919860835260 Pune, India 102 58 Inquiry
Aspen Biopharma Labs Pvt Ltd +91-9248058660 +91-9248058662 Telangana, India 234 58 Inquiry
Ajitha Prodrug India Pvt Ltd +91-9845915533 +91-9845915533 Karnataka, India 17 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
Pharma Affiliates 172-5066494 Haryana, India 6761 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
Hardik Onco Care 08047642620 Ahmedabad, India 7 58 Inquiry
Micro Labs Ltd 08048372692Ext 280 Karnataka, India 16 58 Inquiry
Shaanxi Dideu Medichem Co. Ltd +86-29-81148696 +86-15536356810 China 3320 58 Inquiry

Adriamycin Spectrum

5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- ADRIAMYCIN 14-Hydroxydaunomycin adiblastine (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) Adriacin (hydrochloride salt) Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriblastin Adriblastina (hydrochloride salt) adriblatina (hydrochloride salt) Doxorubicin hydrochloride (hydrochloride salt) Farmablastina (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin hydrochloride (hydrochloride salt) Rubex (hydrochloride salt) 5,12-Naphthacenedione, 10-(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- NSC 123127 ADRIAMYCINSEMIQUINONE (85-cis)-10-[(3-amino-2,3,6-trideoxy-alpha-l-lyxohexapyranosyl)oxy]-7,8,9,10- t adriamycine etrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione DOXOPINHYDROCHLORIDE (85-Cis)-10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-methoxy-5,12-Naphthacenedione (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione NCI-C-01514 10-((3-AMino-2,3,6-trideoxy-α-L-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-Methoxy-5,12-naphthacenedione Doxorubicin base (8S,10S)-10-{[(2R,4S,5S,6S)-4-aMino-5-hydroxy-6-Methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-Methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione Biotransdox Evacet PK 2 Rubidox Doxorubicin Free Base Doxorubincine AdriaMycin, 14-HydroxydaunoMycin, FI 106, K 1039, KW 125, NSC 123127 PROK2 Prokineticin-2 human Protein Bv8 homolog ADRIAMYCIN, PHARMA Adriamycin Adriamycin Adriamycin,98% Doxolem oxorubicin Adriamycin USP/EP/BP Hydroxydaunorubicin Doxorubicin trifluoroacetate salt Epirubicin hydrochloride EP Impurity C Doxorubicin 13CD3Q: What is Doxorubicin 13CD3 Q: What is the CAS Number of Doxorubicin 13CD3 Q: What is the storage condition of Doxorubicin 13CD3 Q: What are the applications of Doxorubicin 13CD3 DoxorubicinQ: What is Doxorubicin Q: What is the CAS Number of Doxorubicin Q: What is the storage condition of Doxorubicin Adriamycin 23214-92-8 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- Doxorubicin hydrohloride